Novellus Therapeutics - Ownership and Business Overview

Life ScienceCompany

Novellus Therapeutics Ownership

Who owns Novellus Therapeutics?

Novellus Therapeutics is owned by Brooklyn ImmunoTherapeutics. It was acquired on June 14, 2021.

Novellus Therapeutics Business Overview

Where is Novellus Therapeutics headquartered?

Novellus Therapeutics is headquartered in Cambridge, Massachusetts.

What sector is Novellus Therapeutics in?

Novellus Therapeutics is a life science company.

When was Novellus Therapeutics founded?

Novellus Therapeutics was founded in 2015.

Life Science M&A Summary in 2021

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2021. The largest life science acquisition in 2021 was Pharmaceutical Product Development - which was acquired by Thermo Fisher Scientific for $17.4B.

Join Mergr to view all 398 acquisitions of life science companies in 2021, including 47 acquisitions by private equity firms, and 351 by strategics.

Novellus Therapeutics

Novellus, Inc.

1035 Cambridge Street, Suite 17B,
Cambridge, Massachusetts 02141
United States,
www.novellus-inc.com

Novellus Therapeutics is a company developing next-generation engineered mesenchymal stem cell therapies using patented mRNA cell reprogramming and gene editing technologies. Novellus Therapeutics was founded in 2015 and is based in Cambridge, Massachusetts.


 Subscribe to unlock this and 209,180
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 202K M&A Transactions
  • 205K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.